title: Etanercept-Induced Pneumonitis: Severe Complication of Tumor Necrosis Factor-Alpha Blocker Treatment.
authors.forename: Abdulla
authors.initials: A
authors.lastname: Watad
authors.forename: Marina
authors.initials: M
authors.lastname: Perelman
authors.forename: Ribhi
authors.initials: R
authors.lastname: Mansour
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Shoenfeld
authors.forename: Howard
authors.initials: H
authors.lastname: Amital
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D018450:Disease Progression; D000068800:Etanercept; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D061705:Image-Guided Biopsy; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007442:Intubation, Intratracheal; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D008875:Middle Aged; D011859:Radiography; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects; D020775:Thoracic Surgery, Video-Assisted / Q000379:methods; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept